Every Form 4 that Belite Bio, Inc (BLTE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BLTE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLTE filings page.
BELITE BIO, INC (BLTE) disclosed that Chief Executive Officer and director Yu-Hsin Lin sold a total of 100,435 American depositary shares of the company in open‑market transactions on September 4 and September 8, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025, at weighted average prices within disclosed ranges between $180 and $198.37 per share.
BELITE BIO, INC (BLTE) director and Chief Financial Officer Chuang Hao-Yuan reported open-market sales of 67,395 American depositary shares on September 4 and September 8, 2026. The ADSs were sold at weighted average prices across ranges from $180 to $198.335 per ADS, pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.
BELITE BIO, INC director and Chief Financial Officer Hao-Yuan Chuang reported selling a total of 367 American depositary shares of the company on August 12, 2026, in two open-market transactions. Each sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.
BELITE BIO, INC director and Chief Executive Officer Lin Yu-Hsin reported selling a total of 365 American depositary shares of the company on 2026-08-12 in two open-market or private transactions at prices of $180.00 and $180.57 per share. Each American depositary share represents one ordinary share with a par value of US$0.0001. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 12/23/2025.
Belite Bio Chief Medical Officer-linked entity sells ADSs. Bioptima Ltd., an entity associated with Chief Medical Officer Hendrik Peter Scholl, reported open-market sales totaling 10,000 American depositary shares of Belite Bio on June 18, 2026. The trades were executed in multiple blocks at prices ranging from about $143.90 to $147.11 per ADS, with some prices disclosed as weighted averages across narrower intraday ranges. Following these transactions, Bioptima Ltd. indirectly holds 15,000 American depositary shares of Belite Bio.
Belite Bio’s Chief Medical Officer, through affiliated entity Bioptima Ltd., reported net open-market sales of 10,000 American depositary shares (ADS) of BLTE on June 16. Each ADS represents one ordinary share. The sales occurred in multiple trades at prices ranging roughly from $137.19 to $145.60, based on weighted-average price disclosures. After these transactions, indirect holdings reported by Bioptima Ltd. stand at 32,946 ADS, indicating the CMO remains a significant indirect holder.
Belite Bio Chief Scientific Officer Nathan L. Mata sold shares of the company in pre-planned trades. On May 7, 2026, he executed four open-market sales totaling 666 American depositary shares at prices ranging from about $152 to $155 per share.
Each American depositary share represents one ordinary share of Belite Bio. The sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following these transactions, Mata reported no American depositary shares held directly and no remaining derivative positions in this filing.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares (ADS) of BELITE BIO, INC in multiple open-market transactions. The sales occurred on May 6, 2026 at prices ranging from about $151.57 to $156.00 per ADS. Each ADS represents one ordinary share of the company. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-arranged rather than timed discretionarily.
Belite Bio, Inc. Chief Scientific Officer Nathan L. Mata reported open-market sales of 1,000 American depositary shares (ADSs) on May 5, 2026. The ADSs were sold in multiple trades at prices ranging from about $153.92 to $158.11.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. Following the transactions, Mata directly holds 1,666 ADSs of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata executed pre-planned open-market sales of 1,000 American depositary shares. On May 4, 2026, he sold ADS in multiple trades between weighted average prices of about $153 and $158, as detailed in the filing.
The sales were carried out under a Rule 10b5-1 trading plan that Mata adopted on December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following these transactions, he directly holds 2,666 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of company stock. On May 1, 2026, he sold a total of 1,000 American depositary shares (ADS), with each ADS representing one ordinary share of Belite Bio.
The sales were executed in multiple trades at prices ranging from about $153.8 to $160 per ADS and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. The filing does not show any option exercises or derivative transactions alongside these sales.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The sales occurred on April 30, 2026 at weighted average prices reported between $155.62 and $158.42 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following the sales, Mata directly holds 4,666 American depositary shares of Belite Bio, Inc.
Belite Bio Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions on April 29, 2026. The sales occurred at weighted average prices ranging from about $154.22 to $158.21, according to the filing footnotes.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. After these sales, Mata directly holds 5,666 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions on April 28, 2026. The ADS were sold in multiple small trades at weighted average prices ranging from $154.62 to $162.59 per ADS.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on December 10, 2025, indicating they were scheduled in advance. Following these transactions, he directly owned 6,666 ADS of the company.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions. The sales occurred on April 27, 2026 at prices ranging from about $160.83 to $164.07 per share. Following these trades, he directly holds 7,666 American depositary shares, each representing one ordinary share of Belite Bio. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, indicating the sales were scheduled in advance rather than timed discretionarily.
Belite Bio chief scientific officer Nathan L. Mata reported open‑market sales of 1,000 American depositary shares (ADS) of the company. The transactions occurred on April 24 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 10, 2025.
The ADS were sold in multiple trades at prices including $162.53 and various weighted average prices in the high‑$150s to low‑$160s. Following these sales, Mata directly owns 8,666 ADS, each representing one ordinary share of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company on April 23, 2026. The sales were open-market transactions at prices ranging from about $164 to $170 per ADS and were executed under a Rule 10b5-1 trading plan adopted on 12/10/2025.
BELITE BIO, INC director and CEO Yu-Hsin Lin reported a compensation-related share vesting. On 04/21/2026, 10,000 ordinary shares were delivered upon vesting of restricted stock units granted on September 15, 2025 after specified performance criteria were met.
Following this non-market transaction, Lin directly holds 182,949 ordinary shares. The event reflects equity-based compensation vesting rather than an open-market purchase or sale.
Belite Bio’s Chief Medical Officer, Hendrik Peter Scholl, reported the vesting of a performance-based stock option held indirectly through Bioptima Ltd. The option covers 10,000 ordinary shares at an exercise price of $77.40 per share.
The option was originally granted on October 7, 2025 and vested on April 21, 2026 after specified performance criteria were met. Following this vesting event, 10,000 stock option rights remain outstanding under this grant, with an expiration date of October 6, 2035. This filing reflects a compensation-related milestone rather than an open-market share purchase or sale.
Belite Bio chief scientific officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The Form 4 shows nine sales of Belite Bio ADS on April 22, 2026, at weighted average prices ranging from about $165.64 to $173.16. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Each ADS represents one ordinary share of Belite Bio.
Belite Bio, Inc. director and Chief Financial Officer Hao-Yuan Chuang reported a compensation-related share change. On April 21, 2026, restricted stock units granted on September 15, 2025 vested upon meeting performance criteria, delivering 10,000 ordinary shares at no stated price.
Following this RSU vesting, Chuang directly holds 205,264 ordinary shares of Belite Bio. The filing reflects an internal equity award vesting rather than an open-market purchase or sale.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open‑market sales of a total of 1,000 American depositary shares on April 21, 2026 at prices within ranges from $163.26 to $167.94. Each ADS represents one ordinary share of the company.
The transactions were executed under a pre‑arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following these sales, Mata holds 11,666 American depositary shares directly.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions. The sales took place on April 20, 2026 at prices generally between about $162 and $168 per ADS. Each ADS represents one ordinary share of the company. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Belite Bio, Inc. Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions. The sales took place on April 17, 2026 at prices generally ranging from about $158 to $163 per share.
Each American depositary share represents one ordinary share of Belite Bio. The filing states that these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of 1,000 American depositary shares on April 16, 2026. The trades were executed at prices within ranges from about $158.16 to $164.22 per share.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, which allows preset selling of shares over time. All transactions involved American depositary shares, each representing one ordinary share of Belite Bio.
Belite Bio’s Chief Scientific Officer, Nathan L. Mata, sold 1,000 American depositary shares in open‑market transactions on April 15, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, and were priced around $167–$171 per share. Following these trades, Mata directly holds 15,666 American depositary shares of Belite Bio.
Belite Bio Chief Executive Officer Lin Yu-Hsin reported open-market sales of 9,200 American depositary shares (ADS) of Belite Bio, Inc. on April 9, 2026. The ADS were sold in multiple transactions at weighted average prices ranging from $180.00 to $183.00 per ADS.
The filing states that these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. After the transactions, Lin held 170,934 ADS directly. Each ADS represents one ordinary share of Belite Bio.
Belite Bio director Wan-Shan Chen sold 1,100 American depositary shares in an open-market transaction. The sale took place on April 9, 2026 at an average price of $180.4301 per ADS. After this sale, Chen directly holds 9,096 ADS. Each ADS represents one ordinary share of Belite Bio. The transaction was executed under a Rule 10b5-1 trading plan that Chen adopted on December 23, 2025, indicating the sale was pre-arranged rather than timed at discretion.
Belite Bio, Inc.'s Chief Financial Officer Hao-Yuan Chuang reported open-market sales of a total of 6,200 American depositary shares on April 9, 2026. The sales were executed in multiple trades at weighted average prices ranging from about $180.35 to $183.08, pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 22, 2025. Following these transactions, Chuang directly holds 93,800 American depositary shares, which each represent one ordinary share of the company.
Belite Bio director Chen Wan-Shan reported a compensation-related stock option award. On 3/31/2026, Chen acquired options to purchase 13,796 ordinary shares at an exercise price of 0.4386 per share, expiring on 12/22/2030.
According to the disclosure, these options stem from a grant originally issued on 12/23/2020 that vests upon meeting specific performance criteria. One such criterion was achieved on 3/31/2026, causing 13,796 additional ordinary shares to vest under the option. This is not an open-market buy or sell but a performance-based equity award.
Belite Bio’s Chief Financial Officer Hao-Yuan Chuang acquired additional vested stock options tied to performance goals. On the satisfaction of a performance criterion on March 31, 2026, an option vested as to 144,868 ordinary shares under a grant originally made on December 23, 2020.
The option has an exercise price of $0.4386 per share and an expiration date of December 22, 2030. After this vesting event, the CFO holds options exercisable for a total of 289,736 ordinary shares under this grant.
Belite Bio Chief Scientific Officer Nathan L. Mata had additional stock options vest tied to performance goals. An existing option grant from April 18, 2022 vested as to 144,868 ordinary shares on March 31, 2026 after a performance criterion was met.
The vested option covers ordinary shares at an exercise price of $6.00 per share and now totals 267,934 exercisable shares, including 123,066 shares that had previously vested. This is a compensation-related award, not an open-market stock purchase or sale.
Belite Bio director and CEO Yu-Hsin Lin reported a vesting-related stock option event tied to performance goals. On March 31, 2026, one of the performance criteria for a previously granted option was met, causing an additional 206,954 ordinary shares subject to the option to vest at an exercise price of $0.4386 per share.
This award was originally granted on December 23, 2020 and vests in installments upon meeting specific performance conditions. Following this vesting event, Lin holds options covering a total of 413,908 ordinary shares, all at the same exercise price, as part of compensation rather than an open-market trade.